Cubist Announces First Patient Dosed in Pivotal Global Phase 3 Trial of CXA-201 for Complicated Urinary Tract Infections

Cubist Pharmaceuticals, Inc. CBST today announced the initiation of a pivotal Phase 3 trial of CXA-201 in patients with complicated urinary tract infections. CXA-201 is being developed as a first-line intravenous therapy for the treatment of serious Gram-negative bacterial infections in the hospital, including those caused by multi-drug resistant Pseudomonas aeruginosa. This trial is the first of two planned multicenter, global, double-blind, randomized Phase 3 studies to compare the safety and efficacy of CXA-201 relative to the comparator, levofloxacin, in patients with cUTI.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsFDABiotechnologyHealth Care
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!